Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Borealis Biosciences is a company in the field of next-generation RNA medicines.
Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
Lightship is making clinical trials more accessible for patients and providers to accelerate development of better therapies for all.
A UK-based developer of drugs to treat respiratory diseases
Holmusk is a provider of healthcare data and technology solutions to support the treatment of mental health and chronic diseases.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.
Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development.
Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Cleerly is a digital healthcare company that offers heart disease diagnosis solutions.
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
SiO2 Materials Science is a plastic container designing company.
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
NuvoAir is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions.
Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.
Kedalion Therapeutics is a biotechnology company that develops and commercializes transformative topical ophthalmic therapies.
Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Adicet Bio is a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer
Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.
Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Novartis has invested in 101 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novartis's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 25 different industry categories.
Among tracked funding rounds, Arcus Biosciences received $250.0M in a Post-IPO Equity round. Novartis's total known invested capital is $2.8B.
Novartis's average investment size is $54.3M across its portfolio of 101 companies.
Recent Novartis portfolio additions include Borealis Biosciences, Citryll, LOQUS23 THERAPEUTICS, ONL Therapeutics, Lightship. These companies were founded in 2020 or later.